



Universitat de Lleida

DEGREE CURRICULUM
PSYCHOPHARMACOLOGY

Coordination: BOIX TORRAS, JACINT

Academic year 2020-21

Subject's general information

Subject name	PSYCHOPHARMACOLOGY			
Code	102921			
Semester	1st Q(SEMESTER) CONTINUED EVALUATION			
Typology	Degree	Course	Character	Modality
	Bachelor's Degree in Psychology	4	OPTIONAL	Attendance-based
Course number of credits (ECTS)	6			
Type of activity, credits, and groups	Activity type	PRAULA		TEORIA
	Number of credits	1.8		4.2
	Number of groups	1		1
Coordination	BOIX TORRAS, JACINT			
Department	EXPERIMENTAL MEDICINE			
Important information on data processing	Consult this link for more information.			

Teaching staff	E-mail addresses	Credits taught by teacher	Office and hour of attention
BESTENE MEDINA, SHEREZADE	sherezade.bestene@udl.cat	3	
BOIX TORRAS, JACINT	jacint.boix@udl.cat	2	
CLARÀ GARANGOU, MARC	marc.clara@udl.cat	0	
RIBAS FORTUNY, JUDIT	judit.ribas@udl.cat	1	

Learning objectives

Pharmacology has a language and a body of general knowledge that are specific to it and that the student must acquire. In addition, the student must know the groups of psychotropic drugs and their use as medicines, toxins and addiction drugs. The reasoning of the pharmacokinetics and pharmacodynamics aspects is substantial to assimilate the clinical and social aspects that explain the use of psychotropic drugs. These general objectives translate into the following specific ones:

1. To acquire the basic notions of pharmacology (pharmacokinetics and pharmacodynamics) in order to understand the criteria that determine the medical prescription of psychotropic drugs.
2. To know how to position oneself professionally in the context of drug therapies for mental diseases.
3. To master a basic conceptual framework and language that allows the interpretation of the "prospectus" annexed to a psychotropic drug.
4. To master a basic conceptual framework and language that allows a fluent dialogue with the prescribing doctor of psychotropic drugs.
5. To know and identify groups of psychotropic drugs and their uses as drugs, toxins and addiction drugs.
6. To identify adverse reactions for psychotropic drugs.
7. To understand the biological basis of pharmacological dependency phenomena.
8. To understand the bio-psychosocial model in the phenomenon of drug addiction.
9. To know how to act professionally in situations of addiction.

Competences

Basic skills:

CB2 Apply their knowledge to their work or vocation in a professional way and possess the skills that are usually demonstrated by developing and defending arguments and solving problems within their area of study.

CB3 Ability to gather and interpret relevant data (usually within their area of study) to make judgements that include reflection on relevant social, scientific or ethical issues.

CB5 Ability to develop those learning skills necessary to undertake further study with a high degree of autonomy

General Competencies:

CG1 Developing the ability to adapt to new situations and solve problems effectively.

CG8 Identify and evaluate own competencies, skills and knowledge according to the standards of the profession.

CG9 Recognizing diversity and difference as a structural element of the human being, while recognizing,

understanding and respecting the cultural complexity of today's society.

CG10 Respecting the fundamental rights of equality between men and women, the promotion of human rights and the values of a culture of peace and democratic values.

Specific Competencies:

SG1 Identifying and analysing the characteristics and needs of people, groups and organisations, as well as the relevant contexts for the service requested.

CE2 Plan the evaluation of programmes and/or psychological interventions, selecting the appropriate indicators and techniques.

CE3 Apply the techniques for collecting information, obtaining relevant data for the evaluation of programs and/or psychological interventions.

SG4 Analyzing and interpreting the results of psychological evaluation.

CE5 Design and apply a psychological intervention strategy/plan, depending on the contexts or services demanded.

CE6 Respond and act in an appropriate and professional manner, taking into account the attitudes and values of the profession, as well as its code of ethics and deontology, in each and every one of the intervention processes.

CE7 Provide information to users and establish an adequate interpersonal relationship, taking into account the different contexts of professional relations.

CE8 To prepare technical reports, both oral and written, on the results of the evaluation process, of the research or of the services demanded, respecting the ethical commitment that the dissemination of psychological knowledge requires.

CE9 To use the different documentary sources in psychology, to show a mastery of the necessary strategies to access the information and to assess the need for documentary updating.

CE12 Disseminate the knowledge derived from theoretical reviews and from the results of psychological research.

Transversal competences:

CT1 Acquire adequate oral and written comprehension and expression of Catalan and Spanish.

CT3 To acquire training in the use of new technologies and information and communication technologies.

CT5 To acquire essential notions of scientific thought.

Subject contents

Block 1: Generalities of Pharmacology

Topic 1: Pharmacology, Clinical Pharmacology and the world of drugs.

Topic 2: Descriptive and quantitative pharmacokinetics.

Topic 3: Pharmacodynamics and drug interactions.

Block 2: Basic Psychopharmacology

Topic 4: Monoaminergic agonist pharmacology.

Topic 5: Monoaminergic antagonist pharmacology.

Topic 6: Cholinergic pharmacology.

Topic 7: Pharmacology of excitatory and inhibitory neurotransmitters.

Topic 8: Pharmacology of opiates and cannabinoids.

Block 3: Clinical Psychopharmacology

Topic 9: Psychosis and antipsychotics.

Topic 10: Mood disorders: antidepressants and euthymizers.

Topic 11: Anxiety and sleep disorders: anxiolytic and hypnotic drugs.

Topic 12: Disorders for drug abuse: Tobacco, cannabinoids, alcohol, stimulants, hallucinogens, opiates and other drugs.

Methodology

1. Regular lectures.
2. Discussion seminars based on the student analysis and autonomous work on drug summaries provided by the professor.
3. Management of information (reading, searching, selection, etc.).
4. Performance of dossiers, memories or practical activities.

Development plan

The official calendar/schedule of the course will be followed. In the context of the COVID-19 pandemic, face-to-face and non-face-to-face classes have been planned that will surely be affected by the course of the pandemic and the situation of teachers. The degree of uncertainty and unpredictability is very high at the time of writing this teaching guide. In any case, the teachers of this course are engaged to announce in advance the changes that will occur by means of the virtual campus. The announcements and warning section is especially suitable for this purpose. In addition, in the resources section, you will find the teaching material of the lectures performed. If necessary, the test tool will be used for non-face-to-face exams. In a summary, the virtual campus will become crucial for the monitoring and good development of the academic course.

Evaluation

1. A first examination will be carried out on the Generalities (topics 2-3) which, by its approach, can be defined as a problem solving exercise (14 questions). It will generate 28% of the final mark of the subject and, therefore, it will be only once performed.
2. An evaluation will be made based on the realization of practical activities, dossiers or memories (still to be determined), which will generate 22% of the final mark of the subject. It will be only once performed.
3. An examination (40 questions) based on the theory will be carried out (topics 1 and 4-12). It will generate 50% of the final mark of the subject. There will be a second chance to take and pass the exam, if initially is failed.
4. The threshold to pass the subject is placed at a mark of 5. This means a 50%, adding up the three evaluations carried out. There is no minimum mark in any of the 3 evaluation acts that can be incompatible with passing the subject.
5. The student must perform the three exams mentioned before. In other words, being not present in any of the three assessments will imply a non-presentation for the whole academic course.
6. The exams will be face-to-face, objective and test type. Each question will display 4 options of which only one is correct. The blank answer adds 0 points. The wrong answer subtracts $\frac{1}{4}$ of the value assigned to the question.
7. If the exams become non-face-to-face due to the COVID-19 pandemic, they will be conducted through the virtual campus testing tool. In this case, they will become examinations based on statements that must be identified as true or wrong. The correct answer is 1 point. A blank answer means 0 points. The wrong answer penalizes -1 point and, therefore, it neutralizes a correct one.
8. In the final mark, a correction coefficient can be added. The calculation of this coefficient will be explained on the first day of the course. This coefficient will be added only to students who surpass the mark of 6 (60%) in the

theoretical exam. At the discretion of the professors, the coefficient can be modified or not added if aberrant results are obtained.

Bibliography

Books:

- Rang y Dale. Farmacología. (9ª ed.), Elsevier España, 2020
- Farmacología humana. Florez J. et al. (6ª ed.), Elsevier Masson, 2013
- Psicofarmacología Esencial de Stahl. Bases neurocientíficas y aplicaciones prácticas. (4ª ed.), 2014
- Prescribers Guide by Stephen M Stahl. 2017 (6ª ed.), 2017
- Nuevas Drogas Psicoactivas. Dolengevich, H., 2015

Journals:

- Annual Review of Pharmacology and Toxicology (<http://arjournals.annualreviews.org/loi/pharmtox>)
- Trends in Pharmacological Sciences (TIPS), Cell press (<http://www.cell.com/trends/pharmacological-sciences/home>)

Internet (Official Organizations):

- Agencia Española del Medicamento, Ministerio de Sanidad (<https://www.aemps.gob.es/>)
- European Medicines Agency (<http://www.ema.europa.eu/ema/>)
- U.S. Food and Drug Administration (<http://www.fda.gov/default.htm>)

Internet (Other addresses):

- Medline plus (<http://medlineplus.gov/spanish/>)
- Rx List, the internet drug index (<http://www.rxlist.com/>)
- Vademecum online (<http://www.vademecum.es/>)
- Stahl online (<https://stahlonline.cambridge.org/>)